Issued by Taizhou, Zhejiang Province: no transaction of Chinese patent medicine

Note that a large number of proprietary Chinese medicines will be discontinued ▍ recently, Taizhou Medical Insurance Bureau of Zhejiang Province issued the notice on the result of joint purchase of Chinese patent medicine by Taizhou Public medical institutions alliance According to the document, in order to ensure the effective implementation of the transaction results of the 2019 Taizhou Public medical institutions alliance of Chinese patent medicine joint procurement, the relevant implementation requirements are hereby notified as follows: first of all, the transaction results are applicable to all kinds of public medical institutions at all levels in Taizhou City, and the joint procurement cycle is 12 months Secondly, all public medical institutions in Taizhou will execute the transaction results and stop using the products that have not been transacted since October 1, 2019 In addition, Taizhou medical insurance bureau also requires that medical institutions at all levels should not negotiate twice - each medical institution needs to re sign a purchase and sale contract with the supplier according to the joint purchase price within the specified time, and purchase and trade online through the drug and equipment purchase platform of Zhejiang Province, and should not negotiate twice At the same time, Taizhou Medical Insurance Bureau requires that in terms of price management, public medical institutions shall sell at zero plus of the joint purchase price; medical insurance agencies shall settle at the joint purchase price; Taizhou joint purchase price is the actual purchase price of medical institutions (including distribution expenses) ▍ focus on monitoring high-priced drugs in the last part of the notice Taizhou medical insurance bureau also requires all public medical institutions in Taizhou to strictly control the drugs that focus on monitoring the limited use Notice requirements: 1 To strengthen the control of medical expenses, give priority to the use of basic drugs, focus on the monitoring of high-priced drugs, and strictly control the products of "key monitoring, limited use" 2 The unsettled products listed in the 2019 Taizhou Public medical institutions alliance Chinese patent medicine joint procurement catalogue shall not be purchased and reused after October 1, 2019 3 The medical institutions and their responsible persons who do not strictly implement the transaction results, evade or disguise to evade, purchase out of catalog, offline, disguised to depress the price, purchase non transaction products by surprise, or cheat will be investigated for responsibility and seriously dealt with ▍ at present, the price reduction pressure of Chinese patent medicine, Taizhou's purchase results of Chinese patent medicine will be officially started from October 1, that is, one month later, for one year However, the notice also pointed out that during the procurement period, in case of changes in the centralized procurement policies of the state or Zhejiang Province, the joint procurement of drugs in Taizhou will be adjusted accordingly According to saibelan, in addition to Taizhou City, Ningbo City, Zhejiang Province, also carried out joint limited price procurement for proprietary Chinese medicines in 2016 In addition, recently, the health and Health Commission of a city in Jiangsu Province issued a second negotiation document, which directly required the price of domestic Chinese patent medicine to be reduced by 20% -- according to the document, the health and Health Commission of the city required commercial companies to negotiate with manufacturers to reduce the price, and the hospital sold the price to patients according to the negotiated price, and the new price will be implemented on September 1, 2019 Compared with the price reduction of anticancer drugs, generic drugs and 4 + 7 medium-sized drugs, the pressure on the price of Chinese patent medicines seems to be less on the surface However, it is undeniable that there has been a demand for price negotiation and price reduction for traditional Chinese medicine In the long run, it seems difficult for Chinese patent medicine to become a safe haven for price reduction.